SEC Form 4 · accession 0000891293-16-000092
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack W Singer
Officer — EVP, Chief Scientific Officer · Director
Period of report
Jan 29, 2016
Accepted (ET)
Jan 29, 2016 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 29, 2016 | S | 5,100 | $1.17 | D | 1,064,892 | D | |
| Common Stock | Jan 29, 2016 | S | 700 | $1.175 | D | 1,064,192 | D | |
| Common Stock | Jan 29, 2016 | S | 2,500 | $1.18 | D | 1,061,692 | D | |
| Common Stock | Jan 29, 2016 | S | 2,000 | $1.185 | D | 1,059,692 | D | |
| Common Stock | Jan 29, 2016 | S | 1,800 | $1.19 | D | 1,057,892 | D | |
| Common Stock | Jan 29, 2016 | S | 300 | $1.195 | D | 1,057,592 | D | |
| Common Stock | Jan 29, 2016 | S | 2,600 | $1.20 | D | 1,054,992 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan.